{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:36:42Z","timestamp":1794836202897,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is a need to better reflect the patient experience in multiple myeloma (MM), beyond just clinical progression, with the use of a novel endpoint that combines disease progression with patient-reported outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic literature review (SLR) identified relevant MM symptoms, which were narrowed down by experts using a Delphi panel. A post-hoc analysis of the MagnetisMM-3 trial of elranatamab assessed the impact of change in patient-reported outcomes (PROs) on the risk of disease progression or death. A composite endpoint for symptomatic progression-free survival (SPFS) combined these symptoms and PFS (PFS event plus 10-point worsening in pain, fatigue, or poor mobility within 28 days).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The SLR identified 16 symptoms from 34 publications. Delphi consensus was that drowsiness, fatigue, pain, and poor mobility are linked to disease progression. Three symptoms had a significant association with PFS: A 10-point worsening on the 100-point scales for pain, fatigue, and poor mobility corresponded to a 22%, 20%, and 31% increase in risk of progression, respectively. Median SPFS was not reached (95% CI 12.2- not reached).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>SPFS is the first composite endpoint in MM that combines PFS and clinically relevant PROs. The patient-centric approach in the conception of this endpoint allows for a nuanced and comprehensive understanding of the MM patient experience.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14724-6","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:28:53Z","timestamp":1754638133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data"],"prefix":"10.1186","volume":"25","author":[{"given":"Martin","family":"Kort\u00fcm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Theurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Ashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanti","family":"Neff-Baro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Jewiti-Rigondza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaeddine","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"8","key":"14724_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","volume":"18","author":"AK Zaleta","year":"2020","unstructured":"Zaleta AK, Miller MF, Olson JS, et al. Symptom burden, perceived control, and quality of life among patients living with multiple myeloma. J Natl Compr Cancer Netw JNCCN. 2020;18(8):1087\u201395. https:\/\/doi.org\/10.6004\/jnccn.2020.7561.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"10272","key":"14724_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ Van De Donk","year":"2021","unstructured":"Van De Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(21)00135-5.","journal-title":"Lancet"},{"issue":"1","key":"14724_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci Basel Switz. 2021;9(1):3. https:\/\/doi.org\/10.3390\/medsci9010003.","journal-title":"Med Sci Basel Switz"},{"issue":"9","key":"14724_CR4","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017;31(9):1915\u201321. https:\/\/doi.org\/10.1038\/leu.2016.380.","journal-title":"Leukemia"},{"issue":"5","key":"14724_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/cancers17050793","volume":"17","author":"E Ortega-Vida","year":"2025","unstructured":"Ortega-Vida E, Rosado-Rodriguez A, Fe R, Verdugo V, Gavira R, Garz\u00f3n S. Evolution of survival in patients with multiple myeloma over two decades: a real-world experience from a medium-level hospital. Cancers (Basel). 2025;17(5):793. https:\/\/doi.org\/10.3390\/cancers17050793.","journal-title":"Cancers (Basel)"},{"key":"14724_CR6","doi-asserted-by":"publisher","first-page":"djae321","DOI":"10.1093\/jnci\/djae321","volume":"10","author":"A Mafra","year":"2024","unstructured":"Mafra A, Laversanne M, Marcos-Gragera R, et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. JNCI J Natl Cancer Inst Published Online Dec. 2024;10:djae321. https:\/\/doi.org\/10.1093\/jnci\/djae321.","journal-title":"JNCI J Natl Cancer Inst Published Online Dec"},{"issue":"3","key":"14724_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000375392","volume":"38","author":"S Cartier","year":"2015","unstructured":"Cartier S, Zhang B, Rosen VM, et al. Relationship between treatment effects on Progression-Free survival and overall survival in multiple myeloma: A systematic review and Meta-Analysis of published clinical trial data. Oncol Res Treat. 2015;38(3):88\u201394. https:\/\/doi.org\/10.1159\/000375392.","journal-title":"Oncol Res Treat"},{"issue":"5","key":"14724_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.18568","volume":"200","author":"T Etekal","year":"2023","unstructured":"Etekal T, Koehn K, Sborov DW, et al. Time-to\u2010event surrogate end\u2010points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023;200(5):587\u201394. https:\/\/doi.org\/10.1111\/bjh.18568.","journal-title":"Br J Haematol"},{"issue":"2","key":"14724_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","volume":"24","author":"F Efficace","year":"2021","unstructured":"Efficace F, Collins GS, Cottone F, et al. Patient-Reported outcomes as independent prognostic factors for survival in oncology: systematic review and Meta-Analysis. Value Health. 2021;24(2):250\u201367. https:\/\/doi.org\/10.1016\/j.jval.2020.10.017.","journal-title":"Value Health"},{"issue":"11","key":"14724_CR10","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/sj.bjc.6604053","volume":"97","author":"S Siena","year":"2007","unstructured":"Siena S, Peeters M, Van Cutsem E, et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer. 2007;97(11):1469\u201374. https:\/\/doi.org\/10.1038\/sj.bjc.6604053.","journal-title":"Br J Cancer"},{"issue":"4","key":"14724_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/cncr.33315","volume":"127","author":"EE Van Seventer","year":"2021","unstructured":"Van Seventer EE, Fish MG, Fosbenner K, et al. Associations of baseline patient-reported outcomes with treatment outcomes in advanced Gastrointestinal cancer. Cancer. 2021;127(4):619\u201327. https:\/\/doi.org\/10.1002\/cncr.33315.","journal-title":"Cancer"},{"key":"14724_CR12","unstructured":"Knop S, Einsele H, Dhanda D et al. Joint modeling of progression-free survival (PFS) and patient-reported symptoms among relapsed\/refractory multiple myeloma (RRMM) patients. Presented at: ISPOR 2024; May 5, 2024; Atlanta, GA. https:\/\/www.ispor.org\/docs\/default-source\/intl2024\/ispor24dhandapcr209poster135566-pdf.pdf?sfvrsn=dc48425c_0"},{"issue":"2","key":"14724_CR13","first-page":"1","volume":"16","author":"D Fink-Hafner","year":"2019","unstructured":"Fink-Hafner D, Dagen T, Dousak M, Novak M, Hafner-Fink M. Delphi method: strengths and weaknesses. Metodol Zvezki. 2019;16(2):1\u201319.","journal-title":"Metodol Zvezki"},{"issue":"1","key":"14724_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12874-023-01846-3","volume":"23","author":"C Touraine","year":"2023","unstructured":"Touraine C, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C. When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials. BMC Med Res Methodol. 2023;23(1):36. https:\/\/doi.org\/10.1186\/s12874-023-01846-3.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"14724_CR15","first-page":"134","volume":"155","author":"M S\u00e8ne","year":"2014","unstructured":"S\u00e8ne M, Bellera CA, Proust-Lima C. Shared random-effect models for the joint analysis of longitudinal and time-to-event data: application to the prediction of prostate cancer recurrence. J Soci\u00e9t\u00e9 Fr Stat. 2014;155(1):134\u201355.","journal-title":"J Soci\u00e9t\u00e9 Fr Stat"},{"issue":"5","key":"14724_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s11136-021-03040-8","volume":"31","author":"B Cuer","year":"2022","unstructured":"Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C. Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials. Qual Life Res. 2022;31(5):1359\u201370. https:\/\/doi.org\/10.1007\/s11136-021-03040-8.","journal-title":"Qual Life Res"},{"key":"14724_CR17","unstructured":"Cochrane. Cochrane handbook for systematic reviews of interventions. In: Julian PTH, James T, Jacqueline C, Miranda C, Tianjing L, Matthew JP, Vivian AW (eds)\u00a0Wiley Blackwell; 2019. https:\/\/dariososafoula.wordpress.com\/wp-content\/uploads\/2017\/01\/cochrane-handbook-for-systematic-reviews-of-interventions-2019-1.pdf"},{"key":"14724_CR18","unstructured":"National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. 2022. Accessed February 20, 2023. https:\/\/www.nice.org.uk\/process\/pmg20\/resources\/developing-nice-guidelines-the-manual-pdf-72286708700869"},{"key":"14724_CR19","unstructured":"Gemeinsamer Bundesausschuss. The Federal Joint Committee. 2023. Accessed April 25, 2023. https:\/\/www.g-ba.de\/ueber-den-gba\/wer-wir-sind\/"},{"key":"14724_CR20","unstructured":"Marchau V, van der Linde E. The Delphi method. Foresight in organizations. Routledge; 2016: 59\u201379. https:\/\/repository.ubn.ru.nl\/bitstream\/handle\/2066\/170791\/170791.pdf?sequence=1."},{"key":"14724_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jclinepi.2019.03.011","volume":"111","author":"D De Meyer","year":"2019","unstructured":"De Meyer D, Kottner J, Beele H, et al. Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection. J Clin Epidemiol. 2019;111:23\u201331. https:\/\/doi.org\/10.1016\/j.jclinepi.2019.03.011.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"14724_CR22","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"issue":"8","key":"14724_CR23","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"14724_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks K, King MT, Velikova G, et al. Evidence-based guidelines for interpreting change scores for the European organisation for the research and treatment of cancer quality of life questionnaire core 30. Eur J Cancer. 2012;48(11):1713\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2012.02.059.","journal-title":"Eur J Cancer"},{"issue":"11","key":"14724_CR25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43(11):1670\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2007.04.022.","journal-title":"Eur J Cancer"},{"issue":"Supplement 1","key":"14724_CR26","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1182\/blood-2024-203723","volume":"144","author":"M Mohty","year":"2024","unstructured":"Mohty M, Bahlis NJ, Nooka AK, DiBonaventura M, Cappelleri JC, Conte U. The effect of Elranatamab on Patient-Reported outcomes in patients with relapsed\/refractory multiple myeloma Na\u00efve and exposed to B-Cell maturation antigen (BCMA)-Directed therapies: updated Follow-Up from the MagnetisMM-3 study. Blood. 2024;144(Supplement 1):1933\u20131933. https:\/\/doi.org\/10.1182\/blood-2024-203723.","journal-title":"Blood"},{"issue":"SUPPL 1","key":"14724_CR27","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1182\/blood-2021-152984","volume":"138","author":"A Lesokhin","year":"2021","unstructured":"Lesokhin A, Iida S, Stevens D, et al. MagnetisMM-3: an open-label, multicenter, non-randomized phase 2 study of Elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma. Blood. 2021;138(SUPPL 1):1674. https:\/\/doi.org\/10.1182\/blood-2021-152984.","journal-title":"Blood"},{"key":"14724_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","volume":"188","author":"JZ Musoro","year":"2023","unstructured":"Musoro JZ, Coens C, Sprangers MAG, et al. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. Eur J Cancer Oxf Engl 1990. 2023;188:171\u201382. https:\/\/doi.org\/10.1016\/j.ejca.2023.04.027.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"14724_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and Life-Tables. J R Stat Soc. 1972;34(2):187\u2013220.","journal-title":"J R Stat Soc"},{"issue":"4","key":"14724_CR30","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"NM Laird","year":"1982","unstructured":"Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963\u201374.","journal-title":"Biometrics"},{"issue":"1","key":"14724_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4038\/jnsfsr.v37i1.456","volume":"37","author":"W Abeysekera","year":"2009","unstructured":"Abeysekera W, Sooriyarachchi M. Use of schoenfeld\u2019s global test to test the proportional hazards assumption in the Cox proportional hazards model: an application to a clinical study. J Natl Sci Found Sri Lanka. 2009;37(1):41. https:\/\/doi.org\/10.4038\/jnsfsr.v37i1.456.","journal-title":"J Natl Sci Found Sri Lanka"},{"issue":"5","key":"14724_CR32","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"I Mol","year":"2024","unstructured":"Mol I, Hu Y, LeBlanc TW, et al. A matching-adjusted indirect comparison of the efficacy of Elranatamab versus Teclistamab in patients with triple-class exposed\/refractory multiple myeloma. Leuk Lymphoma. 2024;65(5):660\u20138. https:\/\/doi.org\/10.1080\/10428194.2024.2313628.","journal-title":"Leuk Lymphoma"},{"key":"14724_CR33","doi-asserted-by":"publisher","DOI":"10.48550\/ARXIV.1307.5928","author":"A Gelman","year":"2013","unstructured":"Gelman A, Hwang J, Vehtari A. Understanding predictive information criteria for bayesian models. Published Online. 2013. https:\/\/doi.org\/10.48550\/ARXIV.1307.5928.","journal-title":"Published Online"},{"key":"14724_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3447-8","volume-title":"Bayesian survival analysis","author":"JG Ibrahim","year":"2001","unstructured":"Ibrahim JG, Chen MH, Sinha D. Bayesian survival analysis. New York: Springer; 2001. https:\/\/doi.org\/10.1007\/978-1-4757-3447-8."},{"key":"14724_CR35","doi-asserted-by":"publisher","unstructured":"Dudley WN, Wickham PD, Rn, Aocn R, Coombs, Ms N. An introduction to survival statistics: Kaplan-Meier analysis. J Adv Pract Oncol. 2016;7(1). https:\/\/doi.org\/10.6004\/jadpro.2016.7.1.8.","DOI":"10.6004\/jadpro.2016.7.1.8"},{"key":"14724_CR36","unstructured":"Gemeinsamer Bundesausschuss. Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive. Annex XII\u2013 Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Daratumumab (reassessment after the deadline (multiple myeloma, after at least 1 prior therapy, combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone)). Published online September 15, 2022. Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive: Annex XII\u2013 Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Daratumumab (reassessment after the deadline (multiple myeloma, after at least 1 prior therapy, combination with lenalidomide and dexamethasone, or with bortezomib and dexamethasone))."},{"key":"14724_CR37","unstructured":"International Myeloma Foundation. The International Myeloma Foundation Proudly Announces EMA-CHMP Positive Qualification Advice to i2TEAMM Novel Biomarker Procedure Application on the Use of MRDnegCR as an Intermediate Early Endpoint for Conditional Market Approval in Myeloma Clinical Trials. July 2. 2025. Accessed July 9, 2025. https:\/\/www.globenewswire.com\/news-release\/2025\/07\/02\/3109171\/0\/en\/The-International-Myeloma-Foundation-Proudly-Announces-EMA-CHMP-Positive-Qualification-Advice-to-i2TEAMM-Novel-Biomarker-Procedure-Application-on-the-Use-of-MRDnegCR-as-an-Intermed.html"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14724-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14724-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14724-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T19:35:01Z","timestamp":1757360101000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14724-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14724"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14724-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The magnetismm-3 trial was conducted in accordance with the principles of the declaration of helsinki and the international council for harmonisation guidelines for good clinical practice. The protocol and amendments were approved by the memorial sloan kettering cancer center institutional review board\/privacy board as well as institutional review boards at participating sites. An external data monitoring committee was responsible for safety monitoring during the trial and carried out prespecified interim futility and efficacy analyses. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1288"}}